Previous Article | Next Article ![]()
Molecular and Cellular Biology, July 2001, p. 4470-4481, Vol. 21, No. 14
Medical Services, Massachusetts General
Hospital, and Department of Medicine, Harvard Medical School,
Charlestown, Massachusetts 02129
Received 20 March 2000/Returned for modification 25 April
2000/Accepted 28 March 2001
The group IV cytosolic phospholipase A2
(cPLA2) has been localized to the nucleus (M. R. Sierra-Honigmann, J. R. Bradley, and J. S. Pober, Lab.
Investig. 74:684-695, 1996) and is known to translocate from the
cytosolic compartment to the nuclear membrane (S. Glover, M. S. de
Carvalho, T. Bayburt, M. Jonas, E. Chi, C. C. Leslie, and M. H. Gelb, J. Biol. Chem. 270:15359-15367, 1995; A. R. Schievella, M. K. Regier, W. L. Smith, and L. L. Lin,
J. Biol. Chem. 270:30749-30754, 1995). We hypothesized that
nuclear proteins interact with cPLA2 and participate in the
functional effects of this translocation. We have identified a nuclear
protein, cPLA2-interacting protein (PLIP), a splice variant
of human Tip60, which interacts with the amino terminal region of
cPLA2. Like Tip60, PLIP cDNA includes the MYST domain
containing a C2HC zinc finger and well-conserved similarities to
acetyltransferases. Both PLIP and Tip60 coimmunoprecipitate and
colocalize with cPLA2 within the nuclei of transfected COS
cells. A polyclonal antibody raised to PLIP recognizes both PLIP and
Tip60. Endogenous Tip60 and/or PLIP in rat mesangial cells is localized
to the nucleus in response to serum deprivation. Nuclear localization
coincides temporally with apoptosis. PLIP expression, mediated by
adenoviral gene transfer, potentiates serum deprivation-induced
prostaglandin E2 (PGE2) production and
apoptosis in mouse mesangial cells from cPLA2+/+ mice but not in mesangial cells
derived from cPLA2 Phospholipase A2s
(PLA2s) are a heterogeneous family of enzymes that are
defined by their ability to cleave the fatty acid at the
sn-2 position of phospholipids (9, 47). The
group IVA 85-kDa cytosolic phospholipase A2,
cPLA2, is distinguished from other PLA2s by its
activation by submicromolar levels of Ca2+ and its
preference for phospholipid substrates which contain arachidonic acid
at the sn-2 position (18, 26).
cPLA2 has been shown to play a role in many physiological
processes, such as ion channel regulation, cell volume regulation,
macrophage eicosanoid production, and parturition (9, 11,
73), as well as pathophysiologic processes, such as
mitochondrial dysfunction (51), allergic responses
involved in asthma, atopic dermatitis and anaphylaxis, and
ischemia-reperfusion injury to the brain (11, 73).
cPLA2 expression has been associated with cytotoxicity (30, 31, 65, 75).
Although primarily localized to the cytosol in resting cells,
cPLA2 translocates to nuclear membranes when cellular
[Ca2+] is increased to 300 nM (18, 26, 66).
In one study, an intranuclear localization of cPLA2 has
been proposed in subconfluent endothelial cells (67). This
nuclear localization may be critical for physiological and
pathophysiological actions of cPLA2. Arachidonic acid-metabolizing enzymes, such as prostaglandin H2
synthase-1 and -2 (COX-1 and -2) (70) and 5-lipoxygenase
(77, 78), are localized on the nuclear membrane, and
eicosanoids have been found to regulate transcription (3, 7, 8,
24). cPLA2 inhibitors result in reduced levels of
group IIA secretory PLA2 mRNA (46), and
cPLA2 expression has been correlated with COX-2 mRNA
expression (2).
cPLA2 activity is regulated by cytosolic-free
[Ca2+] and phosphorylation. Clark and others have shown
that an amino-terminal [Ca2+]-dependent lipid-binding
(CaLB) domain is both necessary and sufficient for the translocation of
cPLA2 to cellular membranes (18, 52). The CaLB
domain is homologous to domains found in Ras-GAP, phospholipase C, and
PKC Despite the extensive data implicating cPLA2 in multiple
physiological and pathophysiological processes, mechanisms by which cPLA2 acts at the nucleus are incompletely understood. We
hypothesized that nuclear actions of cPLA2 may be
facilitated by nuclear proteins which interact with cPLA2.
A protein, PLIP, which colocalizes in the nucleus with
cPLA2, was isolated using the yeast interaction trap
two-hybrid system. PLIP enhances the cPLA2-dependent
mesangial cell apoptosis and prostaglandin E2
(PGE2) production that occurs in response to serum deprivation.
Plasmids.
pEG202-cPLA2 (1-215) was constructed
by PCR amplification of the amino-terminal fragment of
cPLA2 containing residues 1 to 215 by using the primers
GGAATTCTAATGTCATTTATAGATCCT and CCCAAGCTTTGATTCGTATAATGCCTT and human cPLA2 as
the template. The cDNA of cPLA2 was from
pMT2-cPLA2 (obtained from James Clark, Genetics
Institute, Cambridge, Mass.) (18). This was followed by
cloning of an EcoRI/XhoI fragment of the PCR
product into pEG202. The sequence was verified. A human fibroblast
G0 library cloned into pJG4-5 was obtained from C. Sardet
(then at the Whitehead Institute and Massachusetts Institute of
Technology). pEG202, pSH18-34, pJK101, and pRFHM1 were obtained from
Roger Brent of the Massachusetts General Hospital (28).
PLIP cDNA was ligated from pJG4-5-PLIP into pBluescript and then into
pMT3 EcoRI/Xba sites using the linkers
AATTGAATTCCTCGAGT and CTAGACTCGAGGAATTC. PMT3-Tip60 was created by excising Tip60 cDNA
(obtained from J. Kamine, Yale University, New Haven, Conn.) into
pMT3 using EcoRI and XhoI sites.
Interaction trap two-hybrid screen.
The EGY48 strain of
yeast (obtained from R. Brent), which contains an integrated copy of
the LEU2 gene with upstream activating sequences replaced by 6 LexA
operators (28), was transformed with both a bait plasmid,
pEG202-cPLA2(1-215), and the reporter plasmid, pSH18-34,
by using lithium acetate (25). Yeast colonies containing
both bait and reporter plasmids were selected on Ura Screening of human placenta library.
A human placenta
stretch library in Coprecipitation experiments.
COS cells were
transfected using DEAE-dextran. Cells were plated at 2.5 × 105 in 10-cm plates 24 h prior to transfection. For
each 10-cm plate, 200 µl of 1× phosphate-buffered saline (PBS)
containing DEAE-dextran (10 mg/ml) and chloroquine (2.5 mM) was added
to 5 ml of Dulbecco modified Eagle medium (DMEM) containing 10%
NuSerum (Collaborative Research, Bedford, Mass.). DNA (20 µg/plate)
was added, and the chloroquine-DEAE-dextran-DNA mixture was layered
onto cells. After a 4-h incubation at 37°C, the
chloroquine-DEAE-dextran-DNA mixture was removed and cells were
exposed to 10% dimethyl sulfoxide at room temperature for exactly 2 min. Cells were washed with 1× PBS, and fresh DMEM containing 10%
fetal calf serum (FCS) was added. Forty-eight hours after transfection,
confluent monolayers of transfected cells were harvested into lysis
buffer containing 20 mM Tris (pH 8.0), 50 mM
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.14.4470-4481.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
PLIP, a Novel Splice Variant of Tip60, Interacts
with Group IV Cytosolic Phospholipase A2, Induces
Apoptosis, and Potentiates Prostaglandin Production
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
/
mice. Thus PLIP, a
splice variant of Tip60, interacts with cPLA2 and
potentiates cPLA2-mediated PGE2 production and apoptosis.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(18). cPLA2 is phosphorylated at a
number of sites, including Ser-505, and activated by ERK1/2 (48,
54) and p38 mitogen-activated protein kinase (75).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
, His
,
glucose-containing medium and transformed with the library cDNA in a
GAL1-inducible expression vector, pJG4-5. Transformants were selected
on Ura
, His
, Trp
glucose-containing plates, and 106
CFU were plated onto Ura
, His
, Trp
, Leu
, galactose-raffinose medium. Positive colonies were grown up in Trp
, glucose-containing medium, and isolated prey plasmids were rescued using the method of
Hoffman and Winston (34) and electroporated into KC8
strains of Escherichia coli. PLIP cDNA was cloned into
pBluescript and pMT3 and amplified in XL-1 Blue strains of
E. coli for sequencing and transfection experiments. DNA was
sequenced completely on both strands by using customized
oligonucleotides and standard techniques (5).
gt11 phage was screened in E. coli
Y1090 cells as described previously (5, 64). Briefly,
plaques were immobilized on Gene Screen Plus membranes (New England
Nuclear, Boston, Mass.) with 0.5 N NaOH followed by neutralization in 1 M Tris (pH 7.5). Membranes were prehybridized at 55°C in 2× SDE
(which contains 200 mM NaCl, 100 mM NaPO4 [pH 7.0], and 5 mM EDTA [pH 8.0]) with 5% sodium dodecyl sulfate (SDS), 100 µg of
yeast tRNA/ml, and 100 µg of denatured salmon sperm DNA/ml and
hybridized at 55°C with a 32P-labeled 900-bp fragment of
the 5' end of PLIP cDNA which had been amplified by PCR using the
primers CCATTACATTGACTTCAACA and TTTCACTAATCTCATTGATG.
Membranes were hybridized in 2% SDE overnight and washed in SSC
(1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate) as follows: 15 min
(three times) in 2× SSC at room temperature, followed by 10 min (two
times) in 1× SSC at 65°C, followed by 5 min (two times) in 0.1× SSC.
-glycerophosphate, 2 mM
EDTA, 1% triton, 200 µM vanadate, 100 µM phenylmethylsulfonyl
fluoride, 2 µM leupeptin, 1 mM dithiothreitol, and 10% glycerol.
Immunoprecipitation was done over 4 h at 4°C with a mouse
monoclonal anti-HA antibody diluted 1:10 and protein G agarose beads.
Precipitated proteins were run on a 10% SDS gel at 50 V and
electrophoretically transferred onto Immobilon membranes (Millipore,
Bedford, Mass.). Membranes were blotted with anti-cPLA2
antibody and developed by chemiluminescence.
-glycerophosphate, 1 mM vanadate, 1 mM dithiothreitol, 2 µM
leupeptin, 2 µM pepstatin, 0.5% NP-40, and 0.1% Brij 35. Supernatants were immunoprecipitated with anti-PLIP antibody, and
precipitants were analyzed by Western blotting as described above.
Immunofluorescent microscopy. COS cells were grown to 50% confluence on glass coverslips and transiently transfected using DEAE-dextran as described above. Forty-eight hours after transfection, cells were washed with ice-cold PBS and fixed with 4% paraformaldehyde-0.1% triton over 30 min on ice. Fixed cells were blocked at room temperature in 40% calf serum and exposed to primary and secondary antibodies over 1 h at room temperature with copious washing with PBS in between exposure to antibodies. Primary antibodies were rabbit polyclonal anti-cPLA2 used at 1:100 and mouse monoclonal anti-HA used at 1:5. Secondary antibodies were goat fluorescein isothiocyanate (FITC)-conjugated anti-mouse, rhodamine-conjugated anti-rabbit, and Cy3-conjugated anti-rabbit, all used at 1:100. Cell nuclei were stained with 0.5 µg of Hoechst dye/ml. FITC, rhodamine, and Cy3-conjugated antibodies were obtained from Jackson Immuno Research (West Grove, Pa.).
Production of PLIP antibody.
Supercompetent X-L-1 Blue
E. coli cells were transformed with pGexKg-PLIP. A 5-ml
culture was grown to an optical density at 600 nm of 0.50, induced with
0.2 mM isopropyl-
-
-thiogalactopyranoside (IPTG; Sigma, St. Louis,
Mo.), and incubated overnight at 37°C with agitation. Cells were
harvested and resuspended in 1× binding buffer containing 50 mM Tris
(pH 8.0), 150 mM KCl, and 1% Triton X-100. The suspension was
sonicated at 375W and centrifuged for 20 min at 10,000 × g at 4°C. The supernatant was run over a glutathione agarose
column and washed with 10 volumes of binding buffer. The fusion protein
was eluted with 10 mM glutathione in 1× binding buffer and dialyzed
against 1× binding buffer overnight at 4°C. A rabbit antibody was
made to this protein by SeraSource (Royalston, Mass.).
Cell culture. Rat mesangial cell cultures were derived from 6-week-old Sprague Dawley rats. Cortices of decapsulated, bisected kidneys were minced and forced through a 106-µm sieve (Bellco Glass Co., Vineland, N.J.) followed by passage through a 53-µm sieve. The washed, sieved glomeruli were resuspended in minimal essential medium with D-valine, L-glutamine and Earle's salts (Mediatech, Inc., Herndon, Va.). After excluding fibroblasts by growth in D-valine-containing medium, cells were grown in RPMI with 20% FCS (Mediatech, Inc.). Homogenous cell cultures have been demonstrated using this method (10, 12-14). Mesangial cell cultures were similarly derived from 5-week-old cPLA2-knockout mice and from wild-type control animals (11). Cardiac myocytes were isolated from day-old rats using the neonatal cardiomyocyte isolation system (Worthington Biochemical Corp., Lakewood, N.J.) as described previously (29, 42).
Adenoviral infection.
PLIP cDNA was subcloned into the
NotI and XhoI sites of pADRSV4, which contains
adenoviral sequences from the 0 to 1.2 and 9.2 to 16.1 map units, the
Rous sarcoma virus long-terminal-repeat promoter, and the simian virus
40 early polyadenylation signal to generate pAdRSV4-PLIP. The position
and orientation of the insert were confirmed by sequencing of the 5'
ends of the constructs using a pADRSV4 primer. pADRSV4-PLIP was
cotransfected into 293 cells with pJM17, which contains adenoviral
cDNA. Homologous recombinants between pADRSV4-PLIP and pJM17 contain
exogenous DNA substituted for E1. Individual plaques were purified, and
protein expression was confirmed by immunoblotting. The recombinant
adenovirus was prepared in high titer by propagation in 293 cells and
purification by CsCl gradient. Optimal expression of protein was
determined to occur at 48 to 72 h after infection with 200 to 350 PFU/cell. Infectivity was approximately 50%. A recombinant adenovirus
carrying the E. coli LacZ gene (Ad-Lac) encoding
-galactosidase was used as a control. In other experiments Ad-GFP,
expressing green fluorescent protein, was used as a control.
[3H]arachidonic acid release. Mesangial cells were plated in six-well dishes and grown to confluence in DMEM and either 0.1 or 10% FCS. Cells were labeled overnight with [3H]arachidonic acid (New England Nuclear). Cells were washed twice in serum-free DMEM containing 0.2% albumin and incubated in DMEM. At the end of 30 min of incubation at 37°C, medium was removed and floating cells were removed from the medium by centrifugation at 20,800 × g. Supernatant was counted. Adherent cells were dissolved in 0.1% triton and counted. Data are expressed as supernatant counts over cellular plus supernatant counts.
Measurement of supernatant PGE2. Anti-PGE2 antibody and PGE2 standard were obtained from Sigma Immunochemicals (St. Louis, Mo.). Supernatant PGE2 was measured by radioimmunoassay per the protocol described by the manufacturer. Briefly, PGE2 standard was diluted to 15 to 1,000 pg/100 µl in buffer containing 0.01 M sodium PBS (pH 7.4), 0.1% bovine serum albumin, and 0.1% sodium azide. One hundred microliters of sample or standard was vortex mixed with 500 µl of anti-PGE2 antibody and incubated at 4°C for 30 min. 3H-PGE2 (New England Nuclear) was added for 1 h at 4°C followed by 200 µl of dextran-coated charcoal suspension. Samples were centrifuged at 2,000 × g for 5 min, and radioactivity in supernatants was determined.
RNA isolation and RT-PCR. RNA was harvested from BALB/c mice using the RNA easy mini kit (Qiagen, Inc., Valencia, Calif.) following the manufacturer's protocol. One-step reverse transcriptase PCR (RT-PCR) (Clontech, Palo Alto, Calif.) was performed using primers TGAGCGGCTGGACCTAAAGAAG and GAATACCGTCAGCACCACGCAT.
Nucleotide sequence accession number. Nucleotide sequence data for PLIP have been submitted to DDBJ/EMBL/GenBank under the accession number U67734.
| |
RESULTS |
|---|
|
|
|---|
Identification of a cPLA2-interacting protein, PLIP. A fragment of cPLA2 cDNA encoding amino acids 1 to 215, which includes the CaLB domain, was cloned into the bait vector, pEG202, to create a fusion protein with the DNA-binding domain of LexA. Using LexA-cPLA2(1-215), we screened 106 clones of a G0 human fibroblast library, which had been cloned into an expression vector, pJG4-5 (28). Restriction analysis and partial sequencing revealed three distinct clones, one of which (no. 55) is the focus of this report.
The interaction between clone 55 and cPLA2(1-215) is specific since cotransformation of yeast with pJG4-5-55 (expressing the interactor) and the bait vector, pEG202-Bicoid, encoding an unrelated LexA fusion protein, does not allow growth on Leu
medium and does not
activate
-galactosidase transcription (data not shown). In yeast,
cPLA2(1-215) coimmunoprecipitates with the interactor when
the latter is immunoprecipitated with an antibody to the hemagglutinin
(HA) epitope tag (data not shown).
PLIP cDNA and amino acid sequence.
The cDNA of clone 55 is
1,840 bp in length with a poly(A) tail (Fig.
1). The cDNA contains a putative
initiator ATG within an optimal Kozak consensus sequence
(45). There is an open reading frame of 1,383 bp encoding
a protein of 461 amino acids with a predicted Mr
of 53,000. The protein was named PLIP for PLA2 interacting protein. A human placenta library (Clontech) was screened using a
900-bp PCR fragment from the 5' end of the cDNA. Eight clones were
isolated, each of which had a 5' origin at, or 3' to, the 5' end of the
pJG4-5-55 cDNA insert and was identical in size. The nonredundant
database of the National Center for Biotechnology Information (NCBI)
was searched with the PLIP cDNA sequence using the GAPPED BLAST program
(1). PLIP is identical to the human TAT-interacting
protein, Tip60 (41), except for a 52-amino-acid fragment
that is present in Tip60 but not PLIP. PLIP and Tip60 cDNA were
compared to the human genomic clone, RP11-856B14 (accession number,
AP001362), which has been partially sequenced and is located on
chromosome 11 and mapped to 11q13. Alignment of PLIP and Tip60 cDNA to
a fragment of clone RP11-856B145 predicted the genomic structure which
is schematically shown in Fig. 2. Clone RP11-856B14 comprises 14 exons. The fifth exon is present in Tip60 but
not PLIP.
|
|
Both PLIP and Tip60 interact and colocalize with cPLA2
in mammalian cells.
To evaluate whether PLIP interacts with
cPLA2 in mammalian cells, PLIP or Tip60 cDNA was cloned
into the mammalian expression vector pMT3, which encodes
the protein with a HA tag at its NH2 terminus. COS cells
were cotransfected with either pEGFP-cPLA2 (for
coimmunoprecipitation experiments) or
pMT2-cPLA2 (for immunofluorescent microscopy)
and with either pMT3-PLIP or pMT3-Tip60.
cPLA2 coimmunoprecipitates with HA-tagged PLIP and Tip60
but not with HA alone (Fig. 3).
|
|
PLIP protein is expressed in multiple cell types.
An antibody
to full-length PLIP was generated in rabbits using a glutathione
S-transferase fusion protein, and cell lines were screened
by Western blot analysis (Fig. 5a). A
faint band at 60 kDa can be seen in all lanes and likely represents
Tip60 (arrow). The lane containing lysate of renal mesangial cells
demonstrates a striking band at approximately 50 kDa, which indicates
that the smaller molecular mass PLIP is also expressed in these cells. This is shown in comparison to lysates of HA-PLIP transfected COS
cells. A larger band at approximately 80 kDa also appears in lanes
containing lysates of MDCK and ecv304 cells, suggesting the possibility
of the existence of larger proteins homologous to Tip60 and PLIP. Both
Tip60 and PLIP RNA are present in mouse tissue (Fig. 5b). RNA was
harvested and purified from BALB/c mouse organs, and RT-PCR was
performed using flanking primers to exon 5. Gel electrophoresis
demonstrates two bands which conform to predicted sizes of 456 and 300, representing cDNAs of Tip60 and PLIP, respectively. To determine
whether PLIP protein was present in nonrenal primary cultured cells,
myocytes were harvested and infected with Ad-PLIP (Fig. 5c). Western
blot analysis of lysates of both Ad-PLIP-infected and Ad-GFP-infected
myocytes shows two bands at 60 to 65 kDa and at 50 kDa, likely
representing Tip60 and PLIP. Ad-PLIP-infected myocytes show an increase
in PLIP-related signal.
|
Serum deprivation results in nuclear localization of PLIP and
causes apoptosis.
Mutations of SAS2 are associated with loss of
viability under conditions of nutrient limitation (63).
Similarly, ESA1 is required for cell growth in yeast (68).
Given PLIP's and Tip60's homology with these proteins, we evaluated
whether PLIP expression is modulated by the presence or absence of
growth factors in serum. Incubation of mesangial cells in 0.25% FCS
induces growth arrest and eventually apoptosis. Using anti-PLIP
antibody, a striking pattern of immunofluorescence was detected in the
nuclei of greater than 95% of renal mesangial cells grown in 0.25%
FCS (
fcs) for 48 h (Fig. 6a,
panels 5 and 6). By contrast, this strong signal was
demonstrated in the nuclei of only 1 or 2 in 50 mesangial cells grown
in 10% FCS (+fcs) (Fig. 6a, panels 1 and 2). There is a small but
significant increase in PLIP-associated signal after only 24 h of
incubation in 0.25% FCS (Fig. 6a, panels 3 and 4). Multiple fields
were examined, and two representative fields are shown. As our antibody
recognizes both PLIP and Tip60, this pattern of immunofluorescence may
reflect either PLIP or Tip60. Nonspecific staining of the nucleus was
ruled out by the observation that preincubation of anti-PLIP antibody
with purified PLIP protein prevented antibody staining of the nucleus
whereas preincubation with albumin had no effect on the staining
pattern (data not shown).
|
|
PLIP expression enhances PGE2 production susceptibility
to apoptosis in +/+ but not
/
cPLA2 mesangial
cells.
Although the nuclear localization of PLIP is temporally
related to the onset of apoptosis, these data do not demonstrate
that PLIP is causally related to apoptosis. cPLA2 has been
associated with apoptosis, however (30, 49, 74, 76, 79),
and our data suggest that loss of cPLA2 from the cytosol
and its accentuation in the nucleus may also be induced by serum
deprivation. To determine whether the PLIP-cPLA2
interaction is functionally relevant to apoptosis, we examined the
effect of adenovirus-mediated PLIP expression in serum-deprived
mesangial cells derived from cPLA2+/+ and
cPLA2
/
mice (11). Although
mouse mesangial cells were resistant to the apoptotic effects of 0.25%
FCS, they were susceptible to apoptosis induced by incubation in
serum-free medium. Ad-PLIP-infected cPLA2+/+
and cPLA2
/
cells were incubated in
serum-free medium for 2 days. PLIP expression, which was equivalent
in cPLA2+/+ and
cPLA2
/
cells (data not shown), results in
a consistent increase in the number of apoptotic cells in
cPLA2+/+ but not
cPLA2
/
cells after serum deprivation (Fig.
8a).
|
/
mesangial cells incubated in
serum-free medium for 48 h. PLIP expression markedly increases
PGE2 production in cPLA2+/+ but not
cPLA2
/
cells (Fig. 8b).
| |
DISCUSSION |
|---|
|
|
|---|
We report that Tip60 and PLIP, a novel splice variant of Tip60, interact and colocalize with group IVA cPLA2. This is a potentially important observation because cPLA2 plays a large role in the production of arachidonic acid, a precursor of eicosanoid-derived metabolites, which are mediators of many physiologic and pathologic cellular processes including inflammation (9, 11, 73). A cPLA2-interacting protein may play a role to modulate the activity and/or intracellular localization of cPLA2 and may serve as a target for antiinflammatory therapies.
Tip60 has been associated with DNA repair (35, 71) and
with both positive and negative transcriptional regulation (16, 20). PLIP and Tip60 belong to a family of proteins characterized by a conserved MYST domain, which consists of a C2HC zinc finger domain
and an acetyltransferase domain (15, 33, 63, 68). Tip60
has histone acetyltransferase activity in vitro (80). Tip60 interacts with Bcl-3, a nuclear member of the I
B family (20), and colocalizes with the interleukin-9 receptor
-chain, suggesting both intranuclear and extranuclear roles
(81).
The role of PLIP may or may not be similar to that of Tip60. The biological significance of the 52-amino-acid fragment present in Tip60 but not in PLIP is not yet apparent. Our data indicate that PLIP is a splice variant of Tip60 that is expressed under physiologic conditions. PLIP mRNA was isolated from two libraries, including a human fibroblast G0 and a human placenta library. Both PLIP and Tip60 mRNAs are present in mouse tissue, and proteins consistent in size with Tip60 and PLIP are expressed in primary mouse neonatal myocytes as well as primary rat renal mesangial cells.
The striking increase in nuclear immunocytochemical staining with anti-PLIP antibody in serum-deprived mesangial cells may be due to either PLIP or Tip60 as the PLIP antibody recognizes both proteins. Western blot analysis of whole-cell lysates does not demonstrate upregulation of total cell PLIP protein, nor of Tip60, after serum deprivation. Thus, neither Tip60 nor PLIP expression is induced by serum deprivation. While the observed enhanced nuclear signal by immunofluorescence after serum deprivation in the absence of a change in total cellular Tip60 and PLIP protein may be related to epitope unmasking, its appearance suggests translocation of the protein from another intracellular site to the nucleus. The model of serum deprivation-induced apoptosis is well described in mesangial cells (72) and nonmesangial cells (27, 36, 37, 39). Apoptosis in mesangial cells in vivo may play an important role in determining the outcome of glomerulonephritis (6). Prominent Tip60 or PLIP nuclear staining correlates temporally with the onset of apoptosis in serum-deprived cells, although the rat mesangial cell model does not permit us to draw a causal relationship between the appearance of Tip60 or PLIP and apoptosis.
cPLA2 has been implicated in tumor necrosis factor
alpha (TNF-
) induced apoptosis, though not in other models. Nuclear
localization of cPLA2 is more evident in serum-deprived
than in serum-replete mesangial cells. We do not believe this is
related to serum deprivation-associated catalytic cleavage of
cytosolic cPLA2 (4) since total expression is
not changed. Additionally, there is a seven- to eightfold increase in
[3H]arachidonic acid release from serum-deprived compared
to serum-replete rat mesangial cells, suggesting activation of
phospholipases. However, multiple phospholipases are active in the
mesangial cell (44, 59). In particular, apoptotic agents
have been shown to increase group II phospholipase A2
(44). In order to determine the biologic relevance of the
PLIP- or Tip60-cPLA2 interaction, it was thus first
necessary to identify the cPLA2-specific contribution to
serum deprivation-induced mesangial cell apoptosis. By selectively expressing PLIP in cells derived from cPLA2+/+
and cPLA2
/
mice, we were able to identify
an effect specific to PLIP and cPLA2. Although the murine
mesangial cells are more resistant to the apoptotic effects of serum
deprivation than rat mesangial cells, apoptosis is potentiated in
serum-deprived cells expressing both PLIP and cPLA2
compared to cells expressing either cPLA2 or PLIP alone.
Cells expressing either PLIP or cPLA2 alone show no
increase in apoptosis compared to cells expressing neither protein,
indicating that the proteins have a synergistic effect on
susceptibility to apoptosis. The synergistic effect of the expression
of both proteins supports the biologic relevance of the
PLIP-cPLA2 interaction.
The effect of PLIP should be placed in the context of other data which
implicate cPLA2 in apoptosis secondary to TNF-
(30, 74, 76, 79) but not Fas (4, 23).
Hayakawa isolated TNF-
-resistant derivatives of L929 cells and
demonstrated that these cells had a marked decrease in TNF-
-induced
arachidonic acid release and a decrease in cPLA2
expression. Expression of murine cPLA2 restored both
TNF-
-induced arachidonic acid release and cytotoxicity
(30). In a wide variety of human melanoma-derived cell
lines, normal epidermal melanocytes, and murine cell lines, cell
susceptibility to apoptosis induced by TNF-
in the presence of
inhibitors of transcription and translation directly correlates with
cPLA2 expression (74) and activity
(79). Inhibitors of caspases inhibit TNF-
-induced
arachidonic acid release and cytotoxity (76), suggesting
that TNF-
-induced cPLA2 activity may require caspase activity.
cPLA2, although not previously implicated in serum deprivation-associated apoptosis, may influence apoptosis via its role in sphingomyelin signaling (38). cPLA2 is necessary for the generation of ceramide, a sphingomyelinase product (57). High levels of ceramide have been demonstrated in Molt-4 leukemia cells in which cycle arrest and apoptosis have been induced by serum withdrawal. The administration of exogenous cell-permeable ceramide to these cells results in cell cycle arrest and apoptosis comparable to that seen after serum withdrawal (40).
TNF-
-induced ceramide accumulation has been demonstrated in
cells susceptible to TNF-
-induced apoptosis. An increase in arachidonic acid release precedes the TNF-
-induced increase in ceramide in HL-60 cells, and the administration of arachidonic acid
activates sphingomyelinase in these cells (35a).
TNF-
-induced arachidonic acid release and ceramide generation is
decreased in a cPLA2-deficient derivative of a murine
fibroblast cell line, suggesting a cPLA2-specific role in
sphingomyelinase activation (38).
PLIP expression markedly increases serum deprivation-induced
PGE2 generation in cPLA2+/+ cells
but has no effect in cPLA2
/
cells. Changes
in renal eicosanoid synthesis may contribute to the matrix production
and cell proliferation seen in glomerular diseases such as diabetes
(21, 50, 61). In contrast to the observed effect on
apoptosis, cPLA2 alone but not PLIP alone also increases
PGE2 production. PGE2 has been shown to have
both anti- (22, 58) and pro- (17, 49, 60)
apoptotic effects. The experimental model does not permit us to
determine whether PGE2 contributes to or protects against
serum deprivation-induced apoptosis.
In summary, we have found that Tip60 and a novel splice variant, PLIP, interact with cPLA2. PLIP potentiates apoptosis and prostaglandin production in renal mesangial cells, two processes critical to the role of mesangial cells in physiologic and pathophysiologic states. Recognition of this interaction may lead to therapeutic approaches which target the PLIP/Tip60-cPLA2 protein complex.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by National Institutes of Health grants DK02356, DK 39773, DK 38452, NS 10828, and DK 54741 and American Heart Association grant-in-aid 9950460N.
We thank R. Brent, E. Golemis, J. Gyuris, and S. Hanes for the vectors used in the two-hybrid interaction trap; C. Sardet for the fibroblast Go library and for invaluable advice on the two-hybrid system; R. Finley for the anti-LexA antibody; J. Settleman for pRc/CMV-GAP plasmid; A. Cybulsky for the anti-cPLA2 antibody; and J. Clark for the pMT2-cPLA2 plasmid. We also thank D. A. Dichek (Gladstone Institute for Cardiovascular Disease) for the pADRSV4-LacZ construct, James Kamine for Tip60 cDNA, and S. Breton for assistance with immunofluorescence microscopy.
| |
ADDENDUM IN PROOF |
|---|
While the manuscript was in preparation Tip60(
), which is
identical to PLIP, was isolated by the laboratory of Pereira-Smith (62).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Massachusetts General Hospital, 149-4002 13th St., Charlestown, MA 02129-2060. Phone: (617) 724-9688. Fax: (617) 726-4356. E-mail: asheridan{at}partners.org.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Altschul, S. F.,
T. L. Madden,
A. A. Schaffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped BLAST and PSI BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
25:3389-3402 |
| 2. | Angel, J., F. Berenbaum, C. Le Denmat, T. Nevalainen, J. Masliah, and C. Fournier. 1994. Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Eur. J. Biochem. 226:125-131[Medline]. |
| 3. | Atluru, D., S. Gudapaty, M. P. O'Donnell, and G. E. Woloschak. 1993. Inhibition of human mononuclear cell proliferation, interleukin synthesis, mRNA for IL-2, IL-6, and leukotriene B4 synthesis by a lipoxygenase inhibitor. J. Leukoc. Biol. 54:269-274[Abstract]. |
| 4. |
Atsumi, G.,
M. Tajima,
A. Hadano,
Y. Nakatani,
M. Murakami, and I. Kudo.
1998.
Fas-induced arachidonic acid release is mediated by Ca2+-independent phospholipase A2 but not cytosolic phospholipase A2, which undergoes proteolytic inactivation.
J. Biol. Chem.
273:13870-13877 |
| 5. | Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1995. Current protocols in molecular biology, vol. 1. John Wiley and Sons, Inc., New York, N.Y. |
| 6. | Baker, A. J., A. Mooney, J. Hughes, D. Lombardi, R. J. Johnson, and J. Savill. 1994. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J. Clin. Investig. 94:2105-2116. |
| 7. | Ben-Menahem, D., Z. Shraga-Levine, R. Limor, and Z. Naor. 1994. Arachidonic acid and lipoxygenase products stimulate gonadotropin alpha-subunit mRNA levels in pituitary alpha T3-1 cell line: role in gonadotropin releasing hormone action. Biochemistry 43:12795-12799. |
| 8. |
Benoit, H.,
M. Jordan,
H. Wagner, and P. D. Wagner.
1999.
Effect of NO, vasodilator prostaglandins, and adenosine on skeletal muscle angiogenic growth factor gene expression.
J. Appl. Physiol.
86:1513-1518 |
| 9. | Bonventre, J. V. 1992. PLA2 and signal transduction. J. Am. Soc. Nephrol. 3:128-150[Abstract]. |
| 10. |
Bonventre, J. V.,
J. H. Gronich, and R. A. Nemenoff.
1990.
Epidermal growth factor enhances glomerular mesangial cell soluble phospholipase A2 activity.
J. Biol. Chem.
265:4934-4938 |
| 11. | Bonventre, J. V., Z. Huang, M. R. Taheri, E. O'Leary, E. Li, M. A. Moskowitz, and A. Sapirstein. 1997. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390:622-625[CrossRef][Medline]. |
| 12. | Bonventre, J. V., K. L. Skorecki, J. I. Kreisberg, and J. Y. Cheung. 1986. Vasopressin increases cytosolic free calcium concentration in glomerular mesangial cells. Am. J. Physiol. 251:F94-F102. |
| 13. | Bonventre, J. V., and M. Swidler. 1988. Calcium dependency of prostaglandin E2 production in rat glomerular mesangial cells. Evidence that protein kinase C modulates the Ca2+-dependent activation of phospholipase A2. J. Clin. Investig. 82:168-176. |
| 14. |
Bonventre, J. V.,
P. C. Weber, and J. H. Gronich.
1988.
PAF and PDGF increase cytosolic [Ca2+] and phospholipase activity in mesangial cells.
Am. J. Physiol.
254:F87-F94 |
| 15. | Borrow, J., V. P. Stanton, J. M. Andresen, R. Becher, F. G. Behm, R. S. Chaganti, C. I. Civin, C. Disteche, I. Dube, A. M. Frischauf, D. Horsman, F. Mitelman, S. Volinia, A. E. Watmore, and D. E. Housman. 1996. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. 14:33-41[CrossRef][Medline]. |
| 16. |
Brady, M. E.,
D. M. Ozanne,
L. Gaughan,
I. Waite,
S. Cook,
D. E. Neal, and C. N. Robson.
1999.
Tip60 is a nuclear hormone receptor coactivator.
J. Biol. Chem.
274:17599-17604 |
| 17. | Brown, D. M., and R. P. Phipps. 1996. Bcl-2 expression inhibits prostaglandin E2-mediated apoptosis in B cell lymphomas. J. Immunol. 157:1359-1370[Abstract]. |
| 18. | Clark, J. D., L. L. Lin, R. W. Kriz, C. S. Ramesha, L. A. Sultzman, A. Y. Lin, N. Milona, and J. L. Knopf. 1991. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell 65:1043-1051[CrossRef][Medline]. |
| 19. |
Clark-Lewis, I.,
J. S. Sanghera, and S. L. Pelech.
1991.
Definition of a consensus sequence for peptide substrate recognition by p44mpk, the meiosis-activated myelin basic protein kinase.
J. Biol. Chem.
266:15180-15184 |
| 20. | Dechend, R., F. Hirano, K. Lehmann, V. Heissmeyer, S. Ansieau, F. G. Wulczyn, C. Scheidereit, and A. Leutz. 1999. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 18:3316-3323[CrossRef][Medline]. |
| 21. | DeRubertis, F. R., and P. A. Craven. 1993. Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. Am. J. Kidney Dis. 22:727-735[Medline]. |
| 22. | Di Popolo, A., A. Memoli, A. Apicella, C. Tuccillo, A. di Palma, P. Ricchi, A. M. Acquaviva, and R. Zarrilli. 2000. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 19:5517-5524[CrossRef][Medline]. |
| 23. | Enari, M., H. Hug, M. Hayakawa, F. Ito, Y. Nishimura, and S. Nagata. 1996. Different apoptotic pathways mediated by Fas and the tumor-necrosis-factor receptor. Cytosolic phospholipase A2 is not involved in Fas-mediated apoptosis. Eur. J. Biochem. 236:533-538[Medline]. |
| 24. | Fukushima, M., T. Kato, S. Narumiya, Y. Mizushima, H. Sasaki, Y. Terashima, Y. Nishiyama, and M. G. Santoro. 1989. Prostaglandin A and J: antitumor and antiviral prostaglandins. Adv. Prostaglandin Thromboxane Leukot. Res. 19:415-418[Medline]. |
| 25. |
Gietz, D.,
A. St. Jean,
R. A. Woods, and R. H. Schiestl.
1992.
Improved method for high efficiency transformation of intact yeast cells.
Nucleic Acids Res.
20:1425 |
| 26. |
Glover, S.,
M. S. de Carvalho,
T. Bayburt,
M. Jonas,
E. Chi,
C. C. Leslie, and M. H. Gelb.
1995.
Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen.
J. Biol. Chem.
270:15359-15367 |
| 27. | Gupta, K., S. Kshirsagar, W. Li, L. Gui, S. Ramakrishnan, P. Gupta, P. Y. Law, and R. P. Hebbel. 1999. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp. Cell Res. 247:495-504[CrossRef][Medline]. |
| 28. | Gyuris, J., E. Golemis, H. Chertkov, and R. Brent. 1993. Cdil, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75:791-803[CrossRef][Medline]. |
| 29. |
Haq, S.,
G. Choukroun,
Z. B. Kang,
H. Ranu,
T. Matsui,
A. Rosenzweig,
J. D. Molkentin,
A. Alessandrini,
J. Woodgett,
R. Hajjar,
A. Michael, and T. Force.
2000.
Glycogen synthase kinase-3 beta is a negative regulator of cardiac hypertrophy.
J. Cell Biol.
151:117-130 |
| 30. |
Hayakawa, M.,
N. Ishida,
K. Takeuchi,
S. Shibamoto,
T. Hori,
N. Oku,
F. Ito, and M. Tsujimoto.
1993.
Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor.
J. Biol. Chem.
268:11290-11295 |
| 31. | Hayakawa, M., S. Jayadev, M. Tsujimoto, Y. A. Hannun, and F. Ito. 1996. Role of ceramide in the stimulation of the transcription of cytosolic phospholipase A2 and cycloxygenase 2. Biochem. Biophys. Res. Commun. 220:681-686[CrossRef][Medline]. |
| 32. | Higashi, S., H. Ohishi, and I. Kudo. 2000. Augmented prostaglandin E2 generation resulting from increased activities of cytosolic and secretory phospholipase A2 and induction of cyclooxygenase-2 in interleukin-1 beta-stimulated rat calvarial cells during the mineralizing phase. Inflamm. Res. 49:102-111[CrossRef][Medline]. |
| 33. | Hilfiker, A., D. Hilfiker-Kleiner, A. Pannuti, and J. C. Lucchesi. 1997. mof, a putative acetyl transferase gene related to the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in Drosophila. EMBO J. 16:2054-2060[CrossRef][Medline]. |
| 34. | Hoffman, C. S., and F. Winston. 1987. A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene 57:267-272[CrossRef][Medline]. |
| 35. | Ikura, T., V. V. Ogryzko, M. Grigoriev, R. Groishman, J. Wang, M. Horikoshi, R. Scully, J. Qin, and Y. Nakatani. 2000. Involvement of the Tip60 histone acetylase complex in DNA repair and apoptosis. Cell 102:463-473[CrossRef][Medline]. |
| 35a. |
Jayadev, S.,
C. M. Linardic, and Y. A. Hannun.
1994.
Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha.
J. Biol. Chem.
269:5757-5763 |
| 36. | Jayadev, S., and Y. A. Hannun. 1996. Ceramide: role in growth inhibitory cascades. J. Lipid. Mediat. Cell Signal. 14:295-301[CrossRef][Medline]. |
| 37. |
Jayadev, S.,
J. C. Barret, and E. Murphy.
2000.
Elevated ceramide is downstream of altered calcium homeostasis in low serum-induced apoptosis.
Am. J. Physiol. Cell Physiol.
279:C1640-C1647 |
| 38. |
Jayadev, S.,
H. L. Hayter,
N. Andrieu,
C. J. Gamard,
B. Liu,
R. Balu,
M. Hayakawa,
F. Ito, and Y. A. Hannun.
1997.
Phospholipase A2 is necessary for tumor necrosis factor -induced ceramide generation in L929 cells.
J. Biol. Chem.
272:17196-17203 |
| 39. |
Jayadev, S.,
J. G. Petranka,
S. K. Cheran,
J. A. Biermann,
J. C. Barrett, and E. Murphy.
1999.
Reduced capacitative calcium entry correlates with vesicle accumulation and apoptosis.
J. Biol. Chem.
274:8261-8268 |
| 40. |
Jayadev, S.,
B. Liu,
A. E. Bielawska,
J. Y. Lee,
F. Nazaire,
M. Y. Pushkareva,
L. M. Obeid, and Y. A. Hannun.
1995.
Role for ceramide in cell cycle arrest.
J. Biol. Chem.
270:2047-2052 |
| 41. | Kamine, J., B. Elangovan, T. Subramanian, D. Coleman, and G. Chinnadurai. 1996. Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-Tat transactivator. Virology 216:357-366[CrossRef][Medline]. |
| 42. |
Kang, J. X., and A. Leaf.
1994.
Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes.
Proc. Natl. Acad. Sci. USA
91:9886-9890 |
| 43. |
Kim, S. S.,
Y. M. Chen,
E. O'Leary,
R. Witzgall, and J. V. Bonventre.
1996.
A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of the zinc finger proteins.
Proc. Natl. Acad. Sci. USA
93:15299-15304 |
| 44. | Konieczkowski, M., and J. R. Sedor. 1993. Cell-specific regulation of type II phospholipase A2 expression in rat mesangial cells. J. Clin. Investig. 92:2524-2532. |
| 45. |
Kozak, M.
1991.
Structural features in eukaryotic mRNAs that modulate the initiation of translation.
J. Biol. Chem.
266:19867-19870 |
| 46. |
Kuwata, H.,
Y. Nakatani,
M. Murakami, and I. Kudo.
1998.
Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3YI fibroblasts.
J. Biol. Chem.
273:1733-1740 |
| 47. |
Leslie, C. C.
1997.
Properties and regulation of cytosolic phospholipase A2.
J. Biol. Chem.
272:16709-16712 |
| 48. |
Lin, L. L.,
A. Y. Lin, and J. L. Knopf.
1992.
Cytosolic PLA2 is coupled to hormonally regulated release of arachidonic acid.
Proc. Natl. Acad. Sci. USA
89:6147-6151 |
| 49. |
Lo, H. H.,
P. Teichmann,
G. Furstenberger,
I. Gimenez-Conti, and S. M. Fischer.
1998.
Suppression or elevation of cytosolic phospholipase A2 alters keratinocyte prostaglandin synthesis, growth and apoptosis.
Cancer Res.
58:4624-4637 |
| 50. | Mahadevan, P., R. G. Larkins, J. R. Fraser, and M. E. Dunlop. 1996. Effect of prostaglandin E2 and hyaluronan on mesangial cell proliferation. A potential contribution to glomerular hypercellularity in diabetes. Diabetes 45:44-50[Abstract]. |
| 51. |
Malis, C. D.,
P. C. Weber,
A. Leaf, and J. V. Bonventre.
1990.
Incorporation of marine lipids into mitochondrial membranes increases susceptibility to damage by calcium and reactive oxygen species: evidence for enhanced activation of phospholipase A2 in mitochondria enriched with n-3 fatty acids.
Proc. Natl. Acad. Sci. USA
87:8845-8849 |
| 52. |
Nalefski, E. A.,
L. A. Sultzman,
D. M. Martin,
R. W. Kriz,
P. S. Towler,
J. L. Knopf, and J. D. Clark.
1994.
Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca2+-dependent lipid-binding domain and a Ca2+-independent catalytic domain.
J. Biol. Chem.
269:18239-18249 |
| 53. |
Naraba, H.,
M. Murakami,
H. Matsumoto,
S. Shimbara,
A. Ueno,
I. Kudo, and S. Ohishi.
1998.
Segregated coupling of phospholipases A2, cyclooxygenases, and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages.
J Immunol.
160:2974-2982 |
| 54. |
Nemenoff, R. A.,
S. Winitz,
N. X. Qian,
V. V. Van Putten,
G. L. Johnson, and L. E. Heasley.
1993.
Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C.
J. Biol. Chem.
268:1960-1964 |
| 55. | Nigg, E. A. 1991. The substrates of the cdc2 kinase. Semin. Cell Biol. 2:261-270[Medline]. |
| 56. | Nigg, E. A. 1993. Targets of cyclin-dependent protein kinases. Curr. Opin. Cell Biol. 5:187-193[CrossRef][Medline]. |
| 57. | Obeid, L. M., and Y. A. Hannun. 1995. Ceramide: a stress signal and mediator of growth suppression and apoptosis. J. Cell. Biochem. 58:191-198[CrossRef][Medline]. |
| 58. | Oshima, M., J. E. Dinchuk, S. L. Kargman, H. Oshima, B. Hancock, E. Kwong, J. M. Trzaskos, J. F. Evans, and M. M. Taketo. 1996. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809[CrossRef][Medline]. |
| 59. | Pfeilschifter, J., and A. Huwiler. 1997. Phospholipase A2 in mesangial cells: control mechanisms and functional importance. Exp. Nephrol. 5:189-193[Medline]. |
| 60. |
Pica, F.,
O. Franzese,
D. D'Onofrio,
E. Bonmassar,
C. Favalli, and E. Garaci.
1996.
Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: a c-Myc-dependent and Bcl-2-independent associated pathway.
J. Pharmacol. Exp. Ther.
277:1793-1800 |
| 61. | Pricci, F., G. Pugliese, P. Mene, G. Romeo, G. Romano, G. Galli, A. Casini, C. M. Rotella, U. DiMario, and F. Pugliesi. 1996. Regulatory role of eicosanoids in extracellular matrix overproduction induced by long-term exposure to high glucose in cultured rat mesangial cells. Diabetologia 39:1055-1062[Medline]. |
| 62. |
Ran, Q., and O. M. Pereira-Smith.
2000.
Identification of an alternatively spliced form of the Tat interactive protein (Tip60), Tip60 ( ).
Gene
258:141-146[CrossRef][Medline].
|
| 63. | Reifsnyder, C., J. Lowell, A. Clarke, and L. Pillus. 1996. Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases. Nat. Genet. 14:42-49[CrossRef][Medline]. |
| 64. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 65. |
Sapirstein, A.,
R. A. Spech,
R. Witzgall, and J. V. Bonventre.
1996.
Cytosolic phospholipase A2 (PLA2), but not secretory PLA2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells.
J. Biol. Chem.
271:21505-21513 |
| 66. |
Schievella, A. R.,
M. K. Regier,
W. L. Smith, and L. L. Lin.
1995.
Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum.
J. Biol. Chem.
270:30749-30754 |
| 67. | Sierra-Honigmann, M. R., J. R. Bradley, and J. S. Pober. 1996. "Cytosolic" phospholipase A2 is in the nucleus of subconfluent endothelial cells but confined to the cytoplasm of confluent endothelial cells and redistributes to the nuclear envelope and cell junctions upon histamine stimulation. Lab. Investig. 74:684-695[Medline]. |
| 68. |
Smith, E. R.,
A. Eisen,
W. Gu,
M. Sattah,
A. Pannuti,
J. Zhou,
R. G. Cook,
J. C. Lucchesi, and C. D. Allis.
1998.
ESA1 is a histone acetyltransferase that is essential for growth in yeast.
Proc. Natl. Acad. Sci. USA
95:3561-3565 |
| 69. | Songyang, Z., S. Blechner, N. Hoagland, M. F. Hoekstra, H. Piwnica-Worms, and L. C. Cantley. 1994. Use of an oriented peptide library to determine the optimal substrate of protein kinases. Curr. Biol. 4:973-982[CrossRef][Medline]. |
| 70. | Spencer, A. G., J. W. Woods, T. Arakawa, I. I. Singer, and W. L. Smith. 1998. Subcellular localization of prostaglandin endoperoxide H synthase-1 and -2 by immunoelectron microscopy. J. Biol. Chem. 16:9886-9893. |
| 71. |
Sterner, D. E., and S. L. Berger.
2000.
Acetylation of histones and transcription-related factors.
Microbiol. Mol. Biol. Rev.
64:435-459 |
| 72. | Sugiyama, H., N. Kashihara, Y. Maeshima, K. Okamoto, K. Kanao, T. Sekikawa, and H. Makino. 1998. Regulation of survival and death of mesangial cells by extracellular matrix. Kidney Int. 54:1188-1196[CrossRef][Medline]. |
| 73. | Uozumi, N., K. Kume, T. Nagase, N. Nakatani, S. Ishii, F. Tashiro, N. Komagata, K. Maki, K. Ikuta, Y. Ouchi, J. Miyazaki, and T. Shimizu. 1997. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 390:618-622[CrossRef][Medline]. |
| 74. | Voelkel-Johnson, C., T. E. Thorne, and S. M. Laster. 1996. Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells. J. Immunol. 156:201-207[Abstract]. |
| 75. | Waterman, W. H., and R. I. Sha'afi. 1995. A mitogen-activated protein kinase independent pathway involved in the phosphorylation and activation of cytosolic phospholipase A2 in human neutrophils stimulated with tumor necrosis factor-alpha. Biochem. Biophys. Res. Commun. 209:271-278[CrossRef][Medline]. |
| 76. |
Wissing, D.,
H. Mouritzen,
M. Egeblad,
G. G. Poirier, and M. Jaatela.
1997.
Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis.
Proc. Natl. Acad. Sci. USA
94:5073-5077 |
| 77. | Woods, J. W., M. J. Coffey, T. G. Brock, I. I. Singer, and M. Peters-Golden. 1995. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J. Clin. Investig. 95:2035-2046. |
| 78. |
Woods, J. W.,
J. F. Evans,
D. Ethier,
S. Scott,
P. J. Vickers,
L. Hearn,
J. A. Heibein,
S. Charleson, and I. I. Singer.
1993.
5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.
J. Exp. Med.
178:1935-1946 |
| 79. |
Wu, Y. L.,
X. R. Jiang,
A. C. Newland, and S. M. Kelsey.
1998.
Failure to activate cytosolic phospholipase A2 causes TNF resistance in human leukemic cells.
J. Immunol.
160:5929-5935 |
| 80. |
Yamamoto, T., and M. Horikoshi.
1997.
Novel substrate specificity of the histone acetyltransferase activity of HIV-1-Tat interactive protein Tip60.
J. Biol. Chem.
272:30595-30598 |
| 81. |
Zhu, Y. X.,
H. B. Sun,
M. L. Tsang,
J. McMahel,
S. Grigsby,
T. Yin, and Y. C. Yang.
1997.
Critical cytoplasmic domains of human interleukin-9 receptor alpha chain in interleukin-9-mediated cell proliferation and signal transduction.
J. Biol. Chem.
272:21334-21340 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»